I suspect the headline number for sales volume slowing may throw...

I suspect the headline number for sales volume slowing may throw a few people. However I have been collecting quarterly dose data for some time and when you place it in that context things look pretty good.

The previous growth update of 22% was given a bit after 3rd qtr so the estimate for the split of the second half between 3rd & 4th qtr could be out either way by a handful of doses.

Over my entire data series dose sales are tracking a 19.4% exponential growth rate and the last qtr was above trend. Those numbers more than justify for me the current price, if the last bar is an indication of acceleration following SIRFLOX  well.....

4th qtrs. have been strong for a number of years, so now eagerly awaiting AGM dose sales update to see if the latest bar is just a strong 4th qtr or the start of an acceleration.